Whether or not the new Prescription Drug Pricing Reduction Act is a good policy, if it is enacted, its proposals have to work as intended and ensure compliant operationalization, writes Jeremy Docken.
Jeremy Docken
Advertisement
Articles by Jeremy Docken
Pharmaceutical Executive
A look at the systemic problems resulting from the overlap of MDRP and 340B.
Advertisement
Latest Updated Articles
- Non-compliance Costs Hundreds of Millions in Revenue
November 25th 2019
- PDPRA's Operational Challenges
March 2nd 2020
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Foundayo Under National Priority Voucher Program
2
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals
3
Merck Enters $838 Million Research & Development Collaboration with Infinimmune
4
Eli Lilly Enters $7.8 Billion Agreement to Acquire Centessa Pharmaceuticals to Advance Sleep-Wake Treatments
5